Pemigatinib is an inhibitor that targets cholangiocarcinoma with FGFR2 fusions, and it blocks FGFR signaling. It comes in tablets at doses of 4.5 mg, 9 mg, or 13.5 mg.
The suggested dose is 13.5 mg taken once every day for 14 days in a 21-day span. Each bottle holds 14 tablets.
